Aldosterone Breakthrough During Angiotensin II Receptor Blockade in Hypertensive Patients With Diabetes Mellitus | Zendy

Toshi Yoneda | Zendy; Youhei Takeda | Zendy; Mikiya Usukura | Zendy; N. Oda | Zendy; Hiroyuki Takata | Zendy; Yasuo Yamamoto | Zendy; Shigehiro Karashima | Zendy; M YAMAGISHI | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aldosterone Breakthrough During Angiotensin II Receptor Blockade in Hypertensive Patients With Diabetes Mellitus

Author(s) -

Toshi Yoneda,

Youhei Takeda,

Mikiya Usukura,

N. Oda,

Hiroyuki Takata,

Yasuo Yamamoto,

Shigehiro Karashima,

M YAMAGISHI

Publication year - 2007

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1016/j.amjhyper.2007.09.001

Subject(s) - medicine , aldosterone , candesartan , diabetes mellitus , spironolactone , blood pressure , endocrinology , valsartan , renin–angiotensin system , angiotensin receptor , angiotensin ii

Aldosterone is an important pathogenetic factor, independent of the renin-angiotensin system in cardiovascular and renal disease. Aldosterone breakthrough during angiotensin-converting enzyme (ACE) inhibitor therapy was reported in hypertension, diabetes mellitus, and chronic renal disease. It is unclear whether the angiotensin II receptor blocker (ARB) causes aldosterone breakthrough in patients with hypertension and diabetes mellitus, and whether aldosterone breakthrough contributes to renal injury in these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research